Physician's hand on the international normalized ratio level of vitamin K antagonist
Anticoagulation therapy is the mainstay of stroke prevention in atrial fibrillation (AF). Evidence for its clinical value is already well established. In the era of novel oral anticoagulation (NOAC) therapy, regular checkup for international normalized ratio (INR) and dose adjustment are no more necessary. However, vitamin K antagonist (VKA), as a traditional oral anticoagulation agent, still plays a role in certain circumstances. The This study is a multicenter noninterventional prospective study.
They included 877 patients from 20 tertiary hospitals in the Republic of Korea. All patients were with AF, older than 20 years and put on VKA. Among them, antiplatelet therapy was prescribed in 229 patients with cardiovascular disease, making the regimen become VKA plus antiplatelet. Other patients, without cardiovascular disease, took VKA alone. The CHA2DS2-VAS scores were similar in both groups. The HAS-BLED was higher in the VKA plus antiplatelet group than the VKA alone group (1.9 ± 0.7 vs 1.3 ± 0.5, P < 0.001). In this SDM model, connecting evidence-based medicine to patientcentered communication skills may achieve optimal patient care. lower INR level. These concerns result in lower INR level and poor TTR performance and may increase the thromboembolism risk of AF patients.
In conclusion, the study in this issue gives us an alert that physician's concern may cause inadvertently inadequate anticoagulation in AF patients with cardiovascular disease. Such behavior may leave patients in a higher risk of thromboembolic events. Since all the Asia guidelines recommend optimal INR level of VKA and the standard dose of NOAC for AF patients, the physicians should give anticoagulant based on evidences, rather than by their preference.
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